SG11202106129RA - Novel approach for treatment of cancer using immunomodulation - Google Patents

Novel approach for treatment of cancer using immunomodulation

Info

Publication number
SG11202106129RA
SG11202106129RA SG11202106129RA SG11202106129RA SG11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA SG 11202106129R A SG11202106129R A SG 11202106129RA
Authority
SG
Singapore
Prior art keywords
immunomodulation
cancer
treatment
novel approach
approach
Prior art date
Application number
SG11202106129RA
Other languages
English (en)
Inventor
Vincent J O'neill
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of SG11202106129RA publication Critical patent/SG11202106129RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202106129RA 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation SG11202106129RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US201962924429P 2019-10-22 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
SG11202106129RA true SG11202106129RA (en) 2021-07-29

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106129RA SG11202106129RA (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Country Status (13)

Country Link
US (1) US20220089733A1 (https=)
EP (1) EP3893869A4 (https=)
JP (2) JP2022512158A (https=)
KR (1) KR20210102259A (https=)
CN (1) CN113260361A (https=)
AU (1) AU2019396206A1 (https=)
BR (1) BR112021011205A2 (https=)
CA (1) CA3121270A1 (https=)
IL (1) IL283742A (https=)
MX (1) MX2021006778A (https=)
SG (1) SG11202106129RA (https=)
TW (1) TW202034955A (https=)
WO (1) WO2020123496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2021158884A1 (en) * 2020-02-07 2021-08-12 Bioxcel Therapeutics, Inc. Treatment regimen for cancer using immunomodulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CA2973040A1 (en) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US11613785B2 (en) * 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Also Published As

Publication number Publication date
JP2025156353A (ja) 2025-10-14
KR20210102259A (ko) 2021-08-19
EP3893869A1 (en) 2021-10-20
TW202034955A (zh) 2020-10-01
JP2022512158A (ja) 2022-02-02
WO2020123496A1 (en) 2020-06-18
CN113260361A (zh) 2021-08-13
BR112021011205A2 (pt) 2021-08-24
EP3893869A4 (en) 2022-08-17
IL283742A (en) 2021-07-29
MX2021006778A (es) 2021-07-15
US20220089733A1 (en) 2022-03-24
AU2019396206A1 (en) 2021-06-17
CA3121270A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ZA201903442B (en) A novel approach for treatment of cancer using immunomodulation
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
EP3630089A4 (en) PROCEDURE FOR CANCER THERAPY
GB201804514D0 (en) Treatment of pyroptosis
SG11202011117VA (en) Treatment of cancer
ZA201902454B (en) Lasofoxifene treatment of er+ breast cancer
IL277981A (en) Cancer treatment methods
IL285807A (en) Immunotherapy for cancer treatment
EP3548028A4 (en) CANCER TREATMENT
IL286297A (en) Minimal residual cancer treatment methods
SG11202010793UA (en) Methods of treating cancer
ZA201908539B (en) Method of treatment of cancer
IL281600B2 (en) Cancer treatment methods
IL263905A (en) Combined cancer treatment
GB201919428D0 (en) Immunotherapeutic treatment of cancer
GB201804515D0 (en) Treatment of necroptosis
IL289201A (en) Compounds for the treatment of cancer
GB201717945D0 (en) Method for treatment of cancer
SG11202107017TA (en) Methods of treating cancer
SG11202106129RA (en) Novel approach for treatment of cancer using immunomodulation
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL274748A (en) Improved cancer treatment
GB201820098D0 (en) Methods of cancer treatment
SG11202011434SA (en) Methods for the treatment of bladder cancer
GB201918815D0 (en) Treatment of cancer